Back to Authors

Walling, Anne M.

https://orcid.org/0000-0001-6026-3249

Mayo Clinic

University of California, Los Angeles

Citations 2

Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases
Asrani, Sumeet K. , Ghabril, Marwan , Kuo, Alexander , Merriman, Raphael B., Morgan, Timothy R. , Parikh, Neehar D. , Ovchinsky, Nadia , Kanwal, Fasiha , Volk, Michael L. , Ho, Chanda , Mehta, Shivang , Cabrera, Roniel , Chernyak, Victoria , El‐Serag, Hashem B. , Ioannou, George N. , Marrero, Jorge A. , Mehta, Neil , Walling, Anne M. , Tapper, Elliot B. , Ghabril, Marwan S , Morgan, Timothy , Serper, Marina , Agopian, Vatche G , Ioannou, George N , Singal, Amit , Salem, Riad , Asrani, Sumeet K , Ovchinsky, Nadia , Parikh, Neehar D , Serper, Marina , Agopian, Vatche G. , Heimbach, Julie K. , Kaplan, David E. , Singal, Amit G. , Taddei, Tamar H

Hepatology | November 15, 2021 | Volume: 75 | Issue: 5 | Pages: 1289-1299

10.1002/hep.32240 Get It

Abstract The burden of HCC is substantial. To address gaps in HCC care, the American Association for the Study of Liver Diseases (AASLD) Practice Metrics Committee (PMC) aimed to develop a standard set of process‐based measures and patient‐reported outcomes (PROs) along the HCC care continuum. We identified candidate process and outcomes measures for HCC care based on structured literature review. A 13‐member panel with content expertise across the HCC care continuum evaluated candidate measures on importance and performance gap using a modified Delphi approach (two rounds of rating) to define the final set of measures. Candidate PROs based on a structured scoping review were ranked by 74 patients with HCC across 7 diverse institutions. Out of 135 measures, 29 measures made the final set. These covered surveillance (6 measures), diagnosis (6 measures), staging (2 measures), treatment (10 measures), and outcomes (5 measures). Examples included the use of ultrasound (± alpha‐fetoprotein [AFP]) every 6 months, need for surveillance in high‐risk populations, diagnostic testing for patients with a new AFP elevation, multidisciplinary liver tumor board (MLTB) review of Liver Imaging‐Reporting and Data System 4 lesions, standard evaluation at diagnosis, treatment recommendations based on Barcelona Clinic Liver Cancer staging, MLTB discussion of treatment options, appropriate referral for evaluation of liver transplantation candidacy, and role of palliative therapy. PROs include those related to pain, anxiety, fear of treatment, and uncertainty about the best individual treatment and the future. The AASLD PMC has developed a set of explicit quality measures in HCC care to help bridge the gap between guideline recommendations and measurable processes and outcomes. Measurement and subsequent implementation of these metrics could be a central step in the improvement of patient care and outcomes in this high‐risk population.
NCCN Guidelines® Insights: Palliative Care, Version 2.2021
Dans, Maria, Kutner, Jean S. , Agarwal, Rajiv , Baker, Justin N. , Bauman, Jessica R. , Carey, Elise C. , Dalal, Shalini , Doberman, Danielle J. , Fecher, Leslie A. , Kapo, Jennifer, Lee, Richard T. , McCammon, Susan , Mitchell, William M. , Ogunseitan, Adeboye, Portman, Diane , Ramchandran, Kavitha , Sutton, Linda , Teply, Melissa , Terauchi, Stephanie , Walling, Anne M. , Zachariah, Finly , Bergman, Mary Anne, Ogba, Ndiya , Campbell, Mallory, Agarwal, Rajiv , Ramchandran, Kavitha J , Beck, Anna Catherine , Campbell, Toby C. , Case, Amy Allen , Epstein, Andrew S , Jones, Joshua , Loggers, Elizabeth T , Mitchell, William, Temel, Jennifer S. , Thomas, Jane deLima

Journal of the National Comprehensive Cancer Network | August 2, 2021 | Volume: 19 | Issue: 7 | Pages: 780-788

10.6004/jnccn.2021.0033 Get It

Palliative care has evolved to be an integral part of comprehensive cancer care with the goal of early intervention to improve quality of life and patient outcomes. The NCCN Guidelines for Palliative Care provide recommendations to help the primary oncology team promote the best quality of life possible throughout the illness trajectory for each patient with cancer. The NCCN Palliative Care Panel meets annually to evaluate and update recommendations based on panel members’ clinical expertise and emerging scientific data. These NCCN Guidelines Insights summarize the panel’s recent discussions and highlights updates on the importance of fostering adaptive coping strategies for patients and families, and on the role of pharmacologic and nonpharmacologic interventions to optimize symptom management.